Association between

The aim of this study was to identify pharmacogenomic biomarkers to predict tegafur-uracil (UFT)-induced liver dysfunction. A total of 68 patients, who were administered UFT, were evaluated using a two-step pharmacogenomics analysis. The first screening revealed the association between five SNPs and...

Full description

Saved in:
Bibliographic Details
Published in:Pharmacogenomics 2019-02, Vol.20 (5), p.353-365
Main Authors: Kamio, Hidenori, Uchiyama, Toshitaka, Kanno, Hitoshi, Onoe, Yoshiko, Saito, Kayoko, Kameoka, Shingo, Kamio, Takako, Okamoto, Takahiro
Format: Article
Language:English
Subjects:
breast cancer
hepatic dysfunction
pharmacogenomics
single nucleotide polymorphism
tegafur/uracil
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:The aim of this study was to identify pharmacogenomic biomarkers to predict tegafur-uracil (UFT)-induced liver dysfunction. A total of 68 patients, who were administered UFT, were evaluated using a two-step pharmacogenomics analysis. The first screening revealed the association between five SNPs and UFT-induced hepatic dysfunction. In the second step, (rs4149056) was found to be the only SNP associated with UFT treatment-related elevation of aspartate aminotransferase (odds ratio: C/C vs T/T = 7.8, C/T vs T/T = 5.7; p = 0.037) and alanine transaminase (odds ratio: C/C vs T/T = 12.2, C/T vs T/T = 4.1; p = 0.034) levels. The polymorphisms are possible predictors of UFT treatment-related hepatic dysfunction.
ISSN:1462-2416
1744-8042
DOI:10.2217/pgs-2018-0100